C-MER Eye Care Holdings Limited (3309) AI Stock Analysis

C-MER Eye Care Holdings Limited

(HKEX:3309)

Select Model

Rating:71Outperform

Price Target:HKD 0.89▲(3.49% Upside)

Action:upgraded

Date:08/06/26

The overall score reflects a balance of solid fundamentals and reasonable valuation against technical and profitability risks. The most important driver is financial performance: a strong, low-leverage balance sheet and improving cash flows underpin resilience, while rapid revenue growth in eye care services adds structural growth potential despite historically volatile margins. Valuation further supports the stock, with a moderate P/E multiple and a small dividend yield that together suggest investors are not overpaying for the recent recovery in profits. Technicals are the main drag, as the share price trades below all key moving averages and momentum remains weak, indicating the market has yet to fully price in the fundamental improvement and that near-term volatility or further downside is possible. Overall, HK:3309 screens as a reasonably valued, financially sound mid-tier healthcare name with meaningful upside if it can sustain margin stability and if technical pressure eases.

Positive Factors

Strong cash generationRecurring positive operating cash flow and strong free cash flow provide internal funding for clinical expansion, facility investment, and shareholder returns. The 2025 improvement in free cash flow also indicates better cash conversion, strengthening financial resilience over the next several quarters.

Negative Factors

Earnings volatilityRepeated swings between losses and profits make future earnings power less predictable and weaken confidence in consistent returns on the company’s medical network. This volatility can constrain reinvestment planning and makes operating performance more dependent on execution in each reporting period.

C-MER Eye Care Holdings Limited (3309) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 1.01B
Dividend Yield: 2.35%
Average Volume (3M): 406.40K
Price to Earnings (P/E): 10.1
Beta (1Y): 0.82
Revenue Growth: 4.75%
EPS Growth: ―
Country: Hong Kong
Employees: 2,200
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

C-MER Eye Care Holdings Limited Business Overview & Revenue Model

Company Description

C-MER Medical Holdings Limited specializes in offering both medical treatments and therapeutic services for a variety of eye conditions. Its business activities are segmented into two primary areas: the delivery of ophthalmological services and the r...

How the Company Makes Money

C-MER primarily makes money by charging patients (and, where applicable, third-party payors) for clinical eye-care services delivered through its own medical network. Key revenue streams typically include: (1) outpatient services such as specialist c...

C-MER Eye Care Holdings Limited Financial Statement Overview

Summary

Financial performance is moderately strong overall: the balance sheet is a clear highlight, with low and declining leverage (debt-to-equity below 0.35, latest 0.24) and an expanding equity base, supporting resilience in a capital-intensive healthcare business. Operating and free cash flows are consistently positive in recent years and have grown sharply into 2025, with cash generation often exceeding net income, signaling sound underlying operations despite some working capital and capex volatility. Revenue growth is robust, rising from HK$1.11B in 2021 to HK$1.95B in 2025 with a 60.6% jump in the latest year, but earnings have been uneven, with net losses in 2022 and 2024 and only a 5.2% net margin in 2025, indicating that profitability is recovering but not yet stable. Taken together, strong balance sheet and improving cash flows support a score above mid-range, but margin inconsistency and EBIT volatility prevent a top-tier rating.

Income Statement

65Positive

Balance Sheet

82Very Positive

Cash Flow

75Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.03B	1.95B	1.91B	1.92B	1.73B	1.11B
Gross Profit	633.13M	603.67M	527.62M	618.96M	365.34M	309.44M
EBITDA	373.27M	341.37M	343.30M	363.38M	194.31M	177.80M
Net Income	100.44M	100.37M	-135.16M	62.00M	-21.88M	21.86M
Balance Sheet
Total Assets	2.86B	2.73B	2.72B	2.75B	2.90B	1.96B
Cash, Cash Equivalents and Short-Term Investments	563.37M	465.96M	467.25M	557.42M	698.51M	442.36M
Total Debt	433.61M	426.78M	437.79M	362.99M	452.49M	471.69M
Total Liabilities	868.58M	796.01M	830.24M	755.35M	903.45M	618.63M
Stockholders Equity	1.83B	1.77B	1.75B	1.85B	1.87B	1.33B
Cash Flow
Free Cash Flow	323.23M	223.94M	124.50M	245.30M	100.63M	19.18M
Operating Cash Flow	400.23M	301.47M	283.12M	361.15M	191.86M	148.41M
Investing Cash Flow	-45.70M	-169.66M	-174.72M	-245.37M	-210.65M	-392.72M
Financing Cash Flow	-196.81M	-212.38M	-194.92M	-242.88M	293.68M	85.12M

C-MER Eye Care Holdings Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price0.86

Price Trends

50DMA0.83Positive

100DMA0.88Negative

200DMA1.09Negative

Market Momentum

MACD0.01Negative

RSI58.14Neutral

STOCH75.64Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3309, the sentiment is Positive. The current price of 0.86 is above the 20-day moving average (MA) of 0.81, above the 50-day MA of 0.83, and below the 200-day MA of 1.09, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 58.14 is Neutral, neither overbought nor oversold. The STOCH value of 75.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3309.

C-MER Eye Care Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

HK:3309 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2219	73Outperform	HKD 1.66B	8.33	6.97%	10.27%	3.85%	-1.23%
HK:3309	71Outperform	HKD 1.05B	10.10	5.57%	2.35%	4.75%	―
HK:1526	68Neutral	HKD 1.47B	4.15	17.86%	2.16%	1.25%	12.60%
HK:3689	64Neutral	HKD 581.85M	5.26	6.35%	10.92%	-0.27%	29.73%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:1846	51Neutral	HKD 703.50M	285.71	0.20%	2.00%	20.54%	-96.74%
HK:3886	41Neutral	HKD 1.10B	78.09	0.48%	1.10%	-3.26%	―

* Healthcare Sector Average

Performance Comparison

HK:3309 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:3309	C-MER Eye Care Holdings Limited	0.85	-0.90	-51.57%
HK:1526	Rici Healthcare Holdings Ltd.	0.93	-0.06	-6.28%
HK:1846	EuroEyes International Eye Clinic Limited	2.20	-1.05	-32.37%
HK:2219	Chaoju Eye Care Holdings Ltd.	2.36	0.06	2.43%
HK:3689	Guangdong Kanghua Healthcare Co., Ltd. Class H	1.74	0.04	2.17%
HK:3886	Town Health International Medical Group Ltd.	0.16	-0.11	-40.07%

C-MER Eye Care Holdings Limited Corporate Events

C-MER Medical Posts Higher Revenue but Softer Adjusted Profit in First Half of 2026

Aug 25, 2026

C-MER Medical Holdings Limited reported unaudited interim results for the six months ended 30 June 2026, showing revenue of HK$1,024.4 million, up 8.5% year on year. Gross profit rose 10.0% to HK$323.4 million and gross margin improved slightly to 31...

C-MER Completes Strategic Investment in CHIGENOVO and Secures Exclusive Rights to ZVS101e

Aug 10, 2026

C-MER Medical Holdings Limited has completed its previously announced investment transactions in CHIGENOVO Co., Ltd., a move that secures a strategic minority stake in the medical company. Through its subsidiary HK (International) Eye Care, C-MER now...

C-MER Medical Sets August Board Meeting to Approve Interim Results and Consider Dividend

Aug 7, 2026

C-MER Medical Holdings Limited has scheduled a board meeting for 25 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider whether to recommend an interim dividend and handle other co...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 06, 2026

C-MER Eye Care Holdings Limited AI Stock Analysis